Evidence map›Paper›PMID 39287735›Full record

ArticleAIDS and behavior2024

Profile of Persons Recently Infected with HIV-1 in Belgium: New Insights to Tailor Prevention Efforts.

C Vanden Bulcke, J Deblonde, C Necsoi, J Van Praet, E Van Cutsem, L Mertens, F Vanroye, K Stoffels, L Debaisieux, V Mortier and 2 more

Abstract read
In one paragraph

Article in AIDS and behavior, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

C Vanden BulckeDepartment of General Internal Medicine, Ghent University Hospital, Ghent, Belgium. charlotte.vandenbulcke@uzgent.be.ORCID http://orcid.org/0009-0008-7754-4424
J DeblondeSciensano, Epidemiology of Infectious Diseases, Brussels, Belgium.
C NecsoiUniv Libre Bruxelles, CHU St Pierre, Serv Malad Infect, Brussels, Belgium.
J Van PraetDepartment Nephrol & Infect Dis, AZ Sint-Jan Brugge AV, Brugge, Belgium.
E Van CutsemDepartment Microbiol, Vrije Univ Brussel, Univ Ziekenhuis Brussel, Brussels, Belgium.
L MertensDepartment Clin Sci, HIV & STD Unit, Inst Trop Med, Med Serv, Antwerp, Belgium.
F VanroyeDepartment Clin Sci, Aids Reference Lab, Clin Reference Lab, Inst Trop Med, Antwerp, Belgium.
K StoffelsAids Reference Lab, Ctr Hosp Univ St Pierre, Brussels, Belgium.
L DebaisieuxAids Reference Lab, Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), CUB Hôpital Erasme, Ixelles, Belgium.
V MortierDepartment Diagnost Sci, Aids Reference Lab, Univ Ghent, Ghent, Belgium.
S CallensDepartment of General Internal Medicine, Ghent University Hospital, Ghent, Belgium.
C VerhofstedeDepartment Diagnost Sci, Aids Reference Lab, Univ Ghent, Ghent, Belgium.

Funding

Gilead Sciences Gilead SciencesViiV Healthcare ViiV Healthcare
6 · The paper itself

Abstract

Despite wide availability of prevention and treatment services, including the ongoing roll-out of pre-exposure prophylaxis (PrEP), the HIV epidemic is not under control in Belgium. Hence, there is a recognized need to improve case finding and early diagnosis to curb the further spread of HIV more effectively. The objective of the present study was to improve insight into the profiles of persons recently infected with HIV-1 and on their prevention trajectory. Between May 2018 and December 2022, we selected persons diagnosed in Belgium within three months of the presumed infection date. We then analyzed information collected using a questionnaire covering topics on HIV testing, sexually transmitted infections (STIs), PrEP use, sexual behavior, partner notification and substance use. The data obtained were analyzed alongside information derived from phylogenetic cluster analysis of the viral source of infection. A total of 93 persons with a recent HIV-1 infection completed the questionnaire, the majority (74%) being MSM, 14% were heterosexual women and 12% were heterosexual men. Nearly one-third of participants engaged in sexual activity with an average of 2 to 5 casual partners around the presumed time of infection. A significant percentage reported frequent substance use during sexual activity (65%), being previously diagnosed with STI (65%) and using condoms infrequently (44%). 63% reported a testing frequency of at least one HIV test per year before being diagnosed and 46% notified their previous sex partner(s) after being diagnosed. Over 20% of respondents (including 11 MSM, 4 heterosexual men and 5 heterosexual women) reported exclusive sexual activity with their steady partner. Eight participants (9%, all MSM, 75% born outside of Belgium) reported PrEP use in the past. No significant differences in behavioral characteristics were found between persons who were part of a local transmission cluster (48%) and persons that were not part of a cluster (47%). The study results revealed that the majority of persons diagnosed early with HIV-1 infection in Belgium exhibited characteristics corresponding to a high-at-risk population and were aware of this risk, as evidenced by a high testing frequency. However, partner notification rates were low and use and awareness of PrEP limited. A notable group of persons not corresponding to the high-risk profiles was also identified. This information may help to expose missed opportunities for prevention and contribute to enhancing the implementation of future prevention measures.

Indexed as

HIV-1HIV InfectionsPre-Exposure ProphylaxisSexual BehaviorSexual PartnersAdultAnti-HIV AgentsBelgiumContact TracingFemaleHeterosexualityHomosexuality, MaleHumansMaleMiddle AgedSubstance-Related DisordersAnti-HIV AgentsHIV- recent infections-transmission clusters-behavior-prevention

Identifiers

PMID39287735
PMCPMC11586297

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.